Paroxysmal Supraventricular Tachycardia (PSVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Paroxysmal Supraventricular Tachycardia (PSVT) Market Outlook

Thelansis’s “Paroxysmal Supraventricular Tachycardia (PSVT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Paroxysmal Supraventricular Tachycardia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Paroxysmal Supraventricular Tachycardia (PSVT) Overview

Paroxysmal supraventricular tachycardia (PSVT) is a type of abnormal heart rhythm known as an arrhythmia characterized by sudden, unpredictable episodes where the heart rate often exceeds 150-200 beats per minute. These episodes can vary in duration, ranging from seconds to days. These episodes typically end abruptly, although gradual disappearance can occur in certain cases. In individuals without overt heart disease, both children and adults may experience chest discomfort due to the sensation of a rapidly beating heart. After an episode, this discomfort may persist in a milder form for a period. This discomfort may be related to myocardial ischemia in older patients with heart disease. Dyspnea, or shortness of breath, can also be a prominent symptom, particularly in patients with pre-existing left ventricular dysfunction, as poor forward cardiac output can worsen pulmonary congestion. PSVT falls into the narrow QRS complex tachycardias category with a regular ventricular response, distinguishing it from conditions like multifocal atrial tachycardia, atrial fibrillation, and atrial flutter. Supraventricular tachycardias (SVTs) are classified based on the origin of the rhythm and whether the rhythm is regular or irregular. Several factors increase the risk of developing PSVT, including alcohol use, caffeine consumption, illicit drug use, and smoking. Symptoms of PSVT often manifest suddenly and can last a few minutes to several hours. These symptoms may include anxiety, a feeling of chest tightness, palpitations (an awareness of the heartbeat, often with an irregular or rapid rate), a rapid pulse, and shortness of breath. In some patients, PSVT may have minimal or no symptoms. In children and infants, persistent PSVT can lead to tachycardia-induced cardiomyopathy, characterized by symptoms such as left ventricular failure, failure to thrive, and fainting. Severe, rapid, or hemodynamically unstable episodes of PSVT can potentially trigger conditions like myocardial infarction, ventricular tachyarrhythmias, and cardiac arrest. The first-line drug treatment for PSVT is adenosine, which is considered a benign arrhythmia. Adenosine and calcium channel blockers have shown promise in safety and efficacy. Adenosine has a relatively short half-life and acts quickly. However, it is associated with higher drug costs, unpleasant side effects, and a higher likelihood of arrhythmia recurrence.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: